Bioretec Ltd. · OMXHEX:BRETEC
Bioretec — Q1 2025 Earnings Presentation
18 slides from Bioretec's earnings presentation, May 21, 2025
Slide 1: Q1 2025 Investor Presentation / 21.5.2025
Q1 2025 Investor Presentation / 21.5.2025
Slide 2: Disclaimer
Disclaimer IMPORTANT INFORMATION This presentation includes forward-looking statements. The words "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim", "target", "might", or, in each case, their negative, or any similar expressions identify certain
Slide 3: Presenting today
Presenting today Sarah van Hellenberg Hubar-Fisher Johanna Salko Interim CEO CFO At Bioretec since 2021 At Bioretec since 2021 Previous experience: Previous experience: 3
Slide 4: The first osteopromotive, load-bearing absorbable orthopedic implant
The first osteopromotive, load-bearing absorbable orthopedic implant ✓ Breakthrough technology: First absorbable osteopromotive magnesium implant approved in the US ✓ Clinically proven: Bone healing in 12 weeks, fully absorbed by the body in 2-3 years ✓ Regulatory authorisations: CE-marked trauma sc
Slide 5: Aiming to transform the orthopedic implant market
Aiming to transform the orthopedic implant market Primary operation Anticipated benefits for Anticipated benefits for surgeons: patients: ✓ Fixation strength on par with ✓ Eliminates the need for traditional metals secondary surgeries ✓ No workflow disruption, same ✓ Reduced risk of patient techniqu
Slide 6: Hypothetical example: RemeOs improving the patient experience
Hypothetical example: RemeOs improving the patient experience Injury occurs Surgery Surgery 4-6 weeks 6+ weeks Removal Recovery surgery ▪ Radiographic control ▪ Radiographic control ▪ Cast removal ▪ K-wires removed ▪ Recovery is faster ▪ Recovery is slower 6
Slide 7: Significant product launches planned in the next 3 years
Significant product launches planned in the next 3 years Global addressable market Mg-Zn-Ca Hybrid alloy composite Short Mid Long term term term $0.9B $2.1B $0.5B $1.4B $2.6B $2.6B Trauma screws DrillPins Staples Plates IM-Nails Spinal Cage 2023→ 2025→ 2026→ 2027→ 2028→ 2028→ Regulatory approvals: C
Slide 8: $10B+ market potential with strong absorbables outlook
$10B+ market potential with strong absorbables outlook Addressable market for full product line-up >$10B… … with strong absorbables outlook Addressable market, 2024 estimate $10.1B $6.6B $1.2B $1.4B Plates Trauma Screw market alone to reach ~$1.2B by 2033 $0.6B Titanium $2.6B IM-Nails (51%) + Titani
Slide 9: Commercialisation in the US underway
Commercialisation in the US underway ▪ In March 2023, the FDA granted market authorization Distribution network & conferences in the US for the RemeOs trauma screw in the US Distributor agreement in place ▪ A controlled launch of the RemeOs trauma screws began Distribution agreement in process in Se
Slide 10: CE-mark approval in EU will accelerate global RemeOs adoption
CE-mark approval in EU will accelerate global RemeOs adoption ▪ CE mark received for the RemeOs Trauma Screw Distribution network & conferences in Europe product portfolio in January 2025 Direct sales ▪ The product portfolio will be launched in Europe through Distribution partner a focused market ap
Slide 11: Q1 update – Ramping up for sustainable growth
Q1 update – Ramping up for sustainable growth Update on Q1 results Key operational milestones Net sales (EURm) Sales margin (%) EBITDA (EURm) ▪ The CE-mark with wide-ranging indications +105% (163%) (89%) for both adults and pediatrics enables the collection of real-world data, supporting 1.4 70% ex
Slide 12: Growing global interest with gradual operational ramp-up ongoing
Growing global interest with gradual operational ramp-up ongoing Appointment of the Transition from an Leverage CE-mark for Continue to expand Attain broader product new Interim CEO R&D-focused global growth the U.S. distribution range FDA approval for organization to a network and focus on RemeOs i
Slide 13: Key investment highlights
Key investment highlights Innovative implant technology aiming to improve patient outcomes 1 • • World’s first and only FDA-approved absorbable metal implants Eliminates the need for unnecessary removal surgeries, reduces infection risk, and promotes faster recovery • Patented magnesium alloy materi
Slide 14: Our vision is a purer world... Thank you.
Our vision is a purer world where technology and biology naturally merge to make healing solutions safer, more reliable and universally accessible Thank you.
Slide 15: Appendix
bioretec Appendix
Slide 16: Management team
Management team Sarah van Hellenberg Johanna Salko Timo Lehtonen Rami Ojala Hubar-Fisher CFO CTO (former CEO) Sales & marketing director Interim CEO At Bioretec since 2021 At Bioretec since 2019 At Bioretec since 2022 At Bioretec since 2021 Previous experience: Previous experience: Previous experien
Slide 17: Board of Directors
Board of Directors Kustaa Poutiainen Michael Piccirillo Päivi Malinen Chair of the Board Bioretec board since 2023 Bioretec board since 2018 Bioretec board since 2022 Previous experience: Previous experience: Previous experience: Sarah van Hellenberg Justin Barad Antti Vasara Hubar-Fisher Bioretec b
Slide 18: Scientific Advisory Board (SAB)
Scientific Advisory Board (SAB) Prof. Dr. Med. Klaus Prof. Dr. Fan Liu Prof. Dr. Jeffrey Prof. Dr. Richard Dresing Wang Assaker Chairman since 2021 Member of SAB since 2021 Member of SAB since 2023 Member of SAB since 2023 Chairman of the AO Chief and Professor in Professor of Orthopaedic Professor